Pre-Eclampsia
Conditions
Brief summary
Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal
Interventions
collect of placenta, blood and urinary samples at delivery
Sponsors
Study design
Eligibility
Inclusion criteria
* pregnant women * With or without vascular pathology
Exclusion criteria
* refusal to participate * multiple pregnancy * major fetal malformation diagnosed during pregnancy follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| genomic analysis on placenta | day of delivery | by chromatin immunoprecipitation-sequencing (ChIP-seq) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| genomic analysis on blood | day of delivery | by ChIP-seq |
| genomic analysis on placenta | day of delivery | by immunohistochemistry an polymerase chain-reaction |
| VEGF blood level | day of delivery | — |
| PLGF blood level | day of delivery | — |
| sFlt1 blood level | day of delivery | — |
| sKDR blood level | day of delivery | — |
Countries
France
Contacts
CHI CRETEIL